Danish pharmaceutical company enters the Middle East
A Danish pharmaceutical company has recently signed a collaboration deal with the Israeli pharmaceutical company Lavi. The CEO of the Danish company sees a double-digit-million potential in the deal.
The Danish company Azanta is now entering the Middle Eastern market through a collaboration deal with Israeli company Lavi. The deal stipulates that Lavi will have the exclusive distribution of the two Azanta drugs Nimoral and Zybrestat in Israel.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
